PT - JOURNAL ARTICLE AU - Baxter, Samantha M. AU - Posey, Jennifer E. AU - Lake, Nicole J. AU - Sobreira, Nara AU - Chong, Jessica X. AU - Buyske, Steven AU - Blue, Elizabeth E. AU - Chadwick, Lisa H. AU - Coban-Akdemir, Zeynep H. AU - Doheny, Kimberly F. AU - Davis, Colleen P. AU - Lek, Monkol AU - Wellington, Christopher AU - Jhangiani, Shalini N. AU - Gerstein, Mark AU - Gibbs, Richard A. AU - Lifton, Richard P. AU - MacArthur, Daniel G. AU - Matise, Tara C. AU - Lupski, James R. AU - Valle, David AU - Bamshad, Michael J. AU - Hamosh, Ada AU - Mane, Shrikant AU - Nickerson, Deborah A. AU - Centers for Mendelian Genomics Consortium AU - Rehm, Heidi L. AU - O’Donnell-Luria, Anne TI - Centers for Mendelian Genomics: A decade of facilitating gene discovery AID - 10.1101/2021.08.24.21261656 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.24.21261656 4099 - http://medrxiv.org/content/early/2021/08/31/2021.08.24.21261656.short 4100 - http://medrxiv.org/content/early/2021/08/31/2021.08.24.21261656.full AB - Mendelian disease genomic research has undergone a massive transformation over the last decade. With increasing availability of exome and genome sequencing, the role of Mendelian research has expanded beyond data collection, sequencing, and analysis to worldwide data sharing and collaboration. Over the last 10 years, the NIH-supported Centers for Mendelian Genomics (CMGs) have played a major role in this research and clinical evolution. We highlight the cumulative gene discoveries facilitated by the program, biomedical research leveraged by the approach, and the larger impact on the research community. Mendelian genomic research extends beyond generating lists of gene-phenotype relationships, it includes developing tools, training the larger community to use these tools and approaches, and facilitating collaboration through data sharing. Thus, the CMGs have also focused on creating resources, tools, and training for the larger community to foster the understanding of genes and genome variation. The CMGs have participated in a wide range of data sharing activities, including deposition of all eligible CMG data into AnVIL (NHGRI’s Genomic Data Science Analysis, Visualization, and Informatics Lab-Space), sharing candidate genes through Matchmaker Exchange (MME) and the CMG website, and sharing variants in Geno2MP and VariantMatcher. The research genomics output remains exploratory with evidence that thousands of disease genes, in which variant alleles contribute to disease, remain undiscovered, and many patients with rare disease remain molecularly undiagnosed. Strengthening communication between research and clinical labs, continued development and sharing of knowledge and tools required for solving previously unsolved cases, and improving access to data sets, including high-quality metadata, are all required to continue to advance Mendelian genomics research and continue to leverage the Human Genome Project for basic biomedical science research and clinical utility.Competing Interest StatementBaylor College of Medicine (BCM) and Miraca Holdings Inc. have formed a joint venture with shared ownership and governance of Baylor Genetics (BG), formerly the Baylor Miraca Genetics Laboratories (BMGL), which performs clinical exome sequencing and Chromosomal Microarray Analysis for genome-wide detection of CNV. JRL serves on the Scientific Advisory Board of BG. JRL has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases and bacterial genomic fingerprinting. HLR receives funding from Illumina to support rare disease gene discovery and diagnosis. Consortium author conflicts of interest are listed in the supplement. Other authors have no disclosures relevant to the manuscript.Funding StatementThe Baylor Hopkins Center for Mendelian Genomics, Broad Institute Harvard Center for Mendelian Genomics, University of Washington Center for Mendelian Genomics, and Yale Center for Mendelian Genomics were funded by the National Human Genome Research Institute (NHGRI) awards UM1HG006542, UM1HG008900, UM1HG006493, and UM1HG006504, respectively. Funds were also provided under the National Heart, Lung, and Blood Institute (NHLBI) under the Trans-Omics for Precision Medicine Program (TOPMed), and the National Eye Institute (NEI). The GSP Coordinating Center (U24HG008956) contributed to cross-program scientific initiatives and provided logistical and general study coordination. Aspects of this work were funded by NHGRI K08HG008986 (JEP), NHGRI R01HG009141 (HLR and DGM), the National Institute of Neurological Disorders and Stroke (NINDS) R35NS105078 (JRL), and National Health and Medical Research Council (NHMRC) Early Career Fellowship 1159456 (NJL). The CMGs would like to thank all of our collaborators from around the world as well as the families and individuals who contributed their data to this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained by collaborators for all participants in studies across the CMGs, and individual-level data, including genomics and clinical data, was de-identified and coded by our collaborators prior to submission to the CMGs. The participant's samples used for this study were obtained from multiple institutions and each CMG (Baylor-Hopkins, Broad Institute of MIT and Harvard, University of Washington, Yale) was responsible for submitting to their own IRB to receive local approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCandidate genes identified by the CMG have been submitted to Matchmaker Exchange (https://www.matchmakerexchange.org/). Variant classifications have been submitted to ClinVar. De-identified genomic and phenotype data have been shared on the National Human Genome Research Institute (NHGRI) AnVIL platform. Data access requests can be made per instructions here https://anvilproject.org/learn/accessing-data/requesting-data-access#accessing-controlled-access-data. https://anvilproject.org/data?query=consortium%3DCMG https://www.ncbi.nlm.nih.gov/clinvar/submitters/505572/ https://www.ncbi.nlm.nih.gov/clinvar/submitters/505755/ https://www.ncbi.nlm.nih.gov/clinvar/submitters/506627/ https://www.ncbi.nlm.nih.gov/clinvar/submitters/505516/ https://www.ncbi.nlm.nih.gov/clinvar/submitters/506150/ http://mendelian.org/phenotypes-genes